Good MorningThe rebound in equities is already over. The S&P 500 opened higher on Wednesday but quickly reversed course to close the session with a loss of 0.75%. The move confirms resistance at the short-term EMA and the high likelihood the index will continue to fall. The critical support level for Thursday trading is 5,185; if broken, the index sell-off will gain momentum as it enters a downtrend.
The initial jobless claims figures may impact Thursday's trading. Although the claims figures are rarely market-moving, they may amplify fears of labor market weakness and the risk of a recession. There is little hope for equities in that scenario as the big money will move out of equities and into safer havens until the threat is passed. Featured: Crypto Genius: Forget bitcoin – this will be so much bigger (Ad) 
|
Markets | | | U.S. stocks slumped Wednesday after a morning rally evaporated, but the losses on Wall Street weren’t as bad as the manic moves that wracked markets worldwide over the last week.The S&P 500 slipped 0.8% after an earlier jump of 1.7% petered out. The Dow Jones Industrial Average fell 234 points, ... Read the Full Story |
|
From Our Partners | | The Tesla Shock Nobody Sees Coming
While headlines scream "Tesla is doomed"...
Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs.
One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd. | | Click here to see the Tesla shock that could blindside everyone. |
|
Stocks | | | U.S. stocks rallied Thursday in Wall Street’s latest sharp swerve after a better-than-expected report on unemployment eased worries about the slowing economy.The S&P 500 jumped 2.3% for its best day since 2022 and shaved off all but 0.5% of its loss from what was a brutal start to the week. The... Read the Full Story |
|
Markets | | |
Super Micro Computer (NASDAQ: SMCI) shares are imploding due to a knee-jerk reaction to weaker-than-expected margin news. However, the takeaways from the earnings report suggest that margin weakness is fleeting and that this dip is buyable. More to the point, the company’s 10-for-1 forward s... Read the Full Story |
|
From Our Partners | | How to Collect Up To $5,917/mo From Trump's Made In USA Boom
Thanks to President Trump's America-First policies, a historic wave of investment is flooding back into the United States: Apple committing a colossal $500 billion to build new U.S. factories. Microsoft injecting $80 billion into domestic manufacturing. Nvidia moving critical chip production back to America.
But here's the hidden opportunity: There's now a groundbreaking way for you to start collecting monthly checks from these very same companies— checks that could reach as high as $5,917 each month.
Don't miss your chance to participate directly in America's industrial comeback. | | Watch Now to Learn How to Get Your First Check in 30 Days |
|
Markets | | |
Super Micro Computer Inc. (NASDAQ: SMCI) stock is down more than 13% the morning after it delivered its fourth quarter and full-year 2024 earnings report. The curiosity isn’t why the stock is down but why it shot higher in the immediate aftermath of the report.
The headline numbers... Read the Full Story |
|
Markets | | | When you make a large purchase, like a house or an automobile, you often need to borrow money to balance your finances. Not everyone has a liquid $400,000 set aside for home ownership, but a more common scenario is a $80,000 down payment and a $320,000 loan from a bank. You get the house, the seller... Read the Full Story |
|
From Our Partners | | Cold War Discovery Could Unlock $100 Trillion in Wealth
Jeff recently traveled to an American ghost town to investigate this crazy Cold War story…
Because it could hold the key to the entire $100 trillion AI boom.
It involves an American ghost town with just 30 people…
And a new twist to the AI boom that could make a lot of people rich. | | Click here to see the details on what could be the biggest tech story of this decade. |
|
Markets | | |
Lyft (NASDAQ: LYFT) released its second quarter 2024 earnings report, revealing a remarkable milestone. Lyft’s financial release shows that the company achieved GAAP profitability for the first time in the company's history. However, this triumph was met with a wave of investor caution as Ly... Read the Full Story |
|
Markets | | |
The Walt Disney Company’s (NYSE: DIS) Q3 results and guidance are solid, leaving many questioning why the stock remains under pressure. The primary reason is a caution that economic pressures will continue to impact demand at the parks. This is critical information because the parks accoun... Read the Full Story |
|
Markets | | | Beyond Meat on Wednesday reported better-than-expected sales in the second quarter despite continuing weak demand for its plant-based burgers, chicken and other products.The El Segundo, California-based company said its revenue fell nearly 9% to $93.2 million for the April-June period. That was bett... Read the Full Story |
|
Markets | | | CVS Health chopped its 2024 forecast for a third time this year and changed the leadership of its health insurance business where it continues to struggle with rising costs.CEO Karen Lynch will lead the insurance segment, replacing Executive Vice President Brian Kane, who is leaving the company abou... Read the Full Story |
|
Markets | | | Lyft shares tumbled to their biggest loss in more than a year on Wednesday after the ride-hailing app reported gross bookings that spooked investors. Shares of Lyft were down close to 13% in midday trading to $9.54 per share, even as the San Francisco company turned in its first quarterly profit, ea... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. | | View Today's Stock Pick |
|
